Public Citizen Petitions FDA for Ban Of Avandia

Chrissie Cole
Contributor
Visit Chrissie Cole on FacebookVisit Chrissie Cole on Twitter
Posted by Chrissie ColeOctober 31, 2008 10:47 PM

Public Citizen, a non-profit group, is petitioning the U.S. Food and Drug Administration (FDA) for an immediate ban of the drug Avandia because the drug can cause death from liver failure and other serious life-threatening risks that far outweigh its benefits.

Avandia, also known by its generic name, rosiglitazone or rosiglitazone maleate, manufactured by GlaxoSmithKline, is prescribed by doctors for the treatment of type 2 diabetes.

While reviewing FDA data, the group discovered 14 unpublished cases of severe drug-induced liver failure, which included 12 deaths.

That risk, as well as other well known health complications associated with Avandia including heart failure, vision loss and bone fractures, was too great to allow marketing of the drug to continue in the U.S., especially while other, safer treatments remain available, the group said in its petition to the FDA.

“The scientific evidence against Avandia is staggering,” said Dr. Sidney Wolfe, director of Public Citizen’s Health Research Group. “These findings should give the FDA the push they need to act quickly to prevent any further needless deaths and health damage caused by this drug.”

0 Comments

Have an opinion about this post? Please consider leaving a comment or subscribing to the feed to have future articles delivered to your feed reader.

Comments for this article are closed.

Subscribe to InjuryBoard Dayton

InjuryBoard Dayton RSS Feeds

Keep up with the latest updates using your favorite RSS reader

Legal Assistance Center

More Info
Better Business Bureau Accredited Business Confidential

Your question will be referred to an attorney near you. If your question is of a legal nature, then by submitting this form you agree you are not forming a formal attorney / client relationship. Read our full privacy policy.

Looking for an InjuryBoard attorney closer to home? Click here.

Subscribe to Blog Updates

Enter your email address if you would like to receive email notifications when comments are made on this post.

Email address